CRWD
CrowdStrike Holdings, Inc.
CRWD's fundamentals are strong, but it looks expensive: trading at 3678x earnings, about five times its usual 717x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CRWD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Unavailable |
CRWD's revenue and cash flow are currently healthy, and its profitability is stable. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CRWD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 153x | $230 | — |
| Cheap | 451x | $27.04 | -88% |
| Fair | 715x | $42.92 | -81% |
| Expensive | 3,337x | $200 | -13% |
| Current | 3,678x | $230 | — |
Historical ranges are pointers, not guarantees.
CRWD's PE is in its expensive range at 3678x. If earnings grow as analysts expect, today's price would be 153x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CRWD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Broad | |
| High |
CRWD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CRWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.50 | +2400% |
| Q3 2026 | $0.06 | +$0.36 |
| Q2 2026 | -$0.03 | +$0.14 |
| Q1 2026 | -$0.16 | -$0.14 |
| Q4 2025 | -$0.32 | -346% |
| Q3 2025 | -$0.30 | -276% |
| Q2 2025 | -$0.17 | -221% |
| Q1 2025 | -$0.02 | -122% |
| Q4 2024 | $0.13 | +$0.15 |
CRWD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CRWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +26% |
| Q2 2026 | $1.4B | +26% |
| Q1 2026 | $1.3B | +23% |
| Q4 2025 | $1.2B | +22% |
| Q3 2025 | $1.2B | +21% |
| Q2 2025 | $1.1B | +20% |
| Q1 2025 | $1.1B | +25% |
| Q4 2024 | $1B | +29% |
CRWD's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | +7.4 points |
| Q2 2026 | -2.2% | +9.1 points |
| Q1 2026 | 1.1% | +9.1 points |
| Q4 2025 | -5.6% | -0.1 points |
| Q3 2025 | -9.7% | -11 points |
| Q2 2025 | -11% | -12 points |
| Q1 2025 | -8.1% | -12 points |
| Q4 2024 | -5.5% | -5.9 points |
CRWD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CRWD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CRWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $405.9M | +34% |
| Q2 2026 | $493.3M | +65% |
| Q1 2026 | $395.4M | +53% |
| Q4 2025 | $314.1M | +27% |
| Q3 2025 | $302.3M | +5.2% |
| Q2 2025 | $298.4M | -11% |
| Q1 2025 | $258.5M | -12% |
| Q4 2024 | $247.4M | -1.9% |
CRWD's free cash flow has been positive every quarter for seven years: $1.6B over the past year, up 45% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CRWD on cash flow, with more consistent year-over-year improvement.
CRWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +12.9M shares |
| 1 year | +4.5% | +44.8M shares |
| 3 years | +7.8% | +75.9M shares |
| 5 years | +15% | +139M shares |
| Available history | +28% | +228M shares |
CRWD has 1B diluted shares, up 4.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $175.6M |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CRWD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CRWD Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CRWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 49.1 | Neutral |
CRWD's weekly RSI is 55 (neutral) and its Stochastic is 49 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CRWD PE vs Technology Sector
| Metric | CRWD | Sector median | Relative |
|---|---|---|---|
| PE | 3,678x | 28x | 13,101% above |
| PE % | 91 | 35 | 56 pts above |
CRWD is trading at 3678x earnings, a 13101% premium to the Technology sector's median of 28x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CRWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $247.4 | 7.1% below |
| 20 week MA | $221.9 | 3.6% above |
| 50 week MA | $163.0 | 41% above |
| 100 week MA | $136.0 | 69% above |
| 200 week MA | $97.5 | 136% above |
CRWD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CRWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.2 | $55.3 | +352% |
| 2021 | $55.3 | $52.9 | -4.3% |
| 2022 | $52.9 | $25.5 | -52% |
| 2023 | $25.5 | $63.8 | +150% |
| 2024 | $63.8 | $88.8 | +39% |
| 2025 | $88.8 | $120.3 | +36% |
| 2026 YTD | $120.3 | $229.9 | +91% |
CRWD has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.